Sumitomo Mitsui Trust Group Inc. cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 4.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 314,417 shares of the biopharmaceutical company’s stock after selling 13,346 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $104,031,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in the business. MV Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $27,000. Golden State Wealth Management LLC boosted its holdings in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 72 shares in the last quarter. 92.97% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals Stock Performance
ALNY traded down $14.03 during trading on Friday, hitting $298.76. The stock had a trading volume of 2,538,135 shares, compared to its average volume of 1,364,197. The firm has a market cap of $39.89 billion, a PE ratio of 81.63 and a beta of 0.27. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 12 month low of $273.11 and a 12 month high of $495.55. The company has a 50 day simple moving average of $296.27 and a 200-day simple moving average of $325.50.
Analysts Set New Price Targets
ALNY has been the topic of several recent research reports. Jefferies Financial Group restated a “hold” rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Chardan Capital reissued a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. HC Wainwright cut their price objective on Alnylam Pharmaceuticals from $510.00 to $470.00 and set a “buy” rating on the stock in a research note on Monday, June 29th. Finally, Morgan Stanley boosted their target price on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $461.05.
Get Our Latest Stock Report on Alnylam Pharmaceuticals
Key Stories Impacting Alnylam Pharmaceuticals
Here are the key news stories impacting Alnylam Pharmaceuticals this week:
- Positive Sentiment: AstraZeneca and Ionis reported a late-stage trial failure for Wainua, a setback that could reduce competitive pressure on Alnylam’s TTR business and support its market share outlook. AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
- Positive Sentiment: Analysts and market commentary said the rival trial miss improves the outlook for Alnylam’s core TTR franchise, reinforcing the bullish reaction in the stock. Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook
- Positive Sentiment: Morgan Stanley raised its price target on Alnylam to $400 from $370, signaling continued analyst support despite keeping an equal-weight rating. Benzinga report on Morgan Stanley price target increase
- Neutral Sentiment: Short-interest data showed no meaningful change, with reported short interest at 0 shares, so this does not appear to be a real trading catalyst.
- Neutral Sentiment: Commentary pieces on valuation and biotech sector strength add context, but they are secondary to the trial-failure news and analyst target revision. Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns
Insider Transactions at Alnylam Pharmaceuticals
In related news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Read More
- Five stocks we like better than Alnylam Pharmaceuticals
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
- MarketBeat Week in Review – 07/06 – 07/10
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
